Starling Oncology, Inc. (NASDAQ:STLN)
| Market Cap | 637.89M+10.2% |
| Revenue (ttm) | 587.24M |
| Net Income | -36.29M |
| EPS | -0.30 |
| Shares Out | 99.98M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 128,317.928 |
| Open | 6.39 |
| Previous Close | 6.43 |
| Day's Range | 6.26 - 6.41 |
| 52-Week Range | 2.32 - 7.13 |
| Beta | 0.42 |
| Analysts | Buy |
| Price Target | n/a |
| Earnings Date | n/a |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About STLN
Starling Oncology, Inc., formerly The Oncology Institute, is a value-based oncology company advancing cancer care in the community setting. Founded in 2007, the company offers cutting-edge, evidence-based cancer treatments, including clinical trials and transfusions, to a large patient population. It operates as an integrated oncology platform serving patients, providers, and health plans across multiple markets with a focus on delivering high-quality, patient-centered care.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$STLN stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in STLN holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by STLN's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
STLN Estimated quarterly lobbying spending
Source: U.S. Senate LDA
STLN Revenue by Segment
| Segment | Revenue | % of All |
|---|---|---|
| Specialty pharmacy revenue | $98.61M | 61.14% |
| Patient services | $58.83M | 36.47% |
| Clinical research trials and other revenue | $3.85M | 2.39% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New STLN patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to STLN from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in STLN
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $14.16M |
| IWMiShares Russell 2000 ETF | $13.12M |
| VXFVanguard Extended Market ETF | $4.75M |
| IWOiShares Russell 2000 Growth ETF | $3.57M |
| VTWOVanguard Russell 2000 ETF | $2.60M |
| XHSState Street SPDR S&P Health Care Services ETF | $2.58M |
Estimated from each fund’s disclosed top holdings × AUM
STLN Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from STLN’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score